Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11002701 | 0.90 | ALDH1A1 (0.55) | L3MBTL1ALDH1A1SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL177662 | 0.83 | MAPT (0.53) | L3MBTL1ALDH1A1MAPTPOLBNPC1 | |
| SCHEMBL15567363 | 0.81 | ALDH1A1 (0.75) | L3MBTL1ALDH1A1SMN1; SMN2MAPTNPC1 | |
| SCHEMBL9264299 | 0.79 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1MAPTPOLBNPC1 | |
| SCHEMBL9760955 | 0.79 | MAPT (0.64) | L3MBTL1ALDH1A1MAPTPOLBNPC1 | |
| SCHEMBL4496741 | 0.79 | MMP13 (0.59) | L3MBTL1ALDH1A1SMN1; SMN2MAPTPOLB | |
| SCHEMBL1532324 | 0.78 | ALDH1A1 (0.58) | L3MBTL1ALDH1A1SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL2103568 | 0.78 | MAPK1 (0.55) | L3MBTL1ALDH1A1SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL13666325 | 0.77 | ALDH1A1 (0.51) | L3MBTL1ALDH1A1SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL28013196 | 0.77 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1SMN1; SMN2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1527046-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004009546-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | L3MBTL1 4639/4885ALDH1A1 2036/4885SMN1; SMN2 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.